GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (OTCPK:NTBLQ) » Definitions » Investments And Advances

NTBLQ (Notable Labs) Investments And Advances : $1.50 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Investments And Advances?

Notable Labs's Investments And Advances for the quarter that ended in Jun. 2024 was $1.50 Mil.

Notable Labs's quarterly Investments And Advances stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil) but then increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($1.50 Mil).


Notable Labs Investments And Advances Historical Data

The historical data trend for Notable Labs's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Investments And Advances Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Investments And Advances
- - -

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Investments And Advances Get a 7-Day Free Trial - - - - 1.50

Notable Labs Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Notable Labs Business Description

Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.